Intuitive Surgical reports developments in robotic-assisted minimally invasive care, centered on its da Vinci surgical systems, da Vinci 5, da Vinci SP, and Ion Endoluminal System. Company news commonly covers procedure volume, system placements, installed-base growth, instruments and accessories revenue, operating lease placements, and share repurchase activity.
Updates also include FDA clearances that expand indications for Intuitive platforms, such as cardiac procedures for da Vinci 5 and additional procedures for da Vinci SP. News about the company also reflects completed commercial expansion in Europe, including direct operations for da Vinci and Ion distribution in Southern European markets.
Intuitive (ISRG) appointed Aaron Martin, Humana’s President of Insurance, to its board of directors, effective January 1, 2027. His addition will expand the board from 10 to 11 members.
Martin oversees strategy, growth, operations and financial performance across Humana’s insurance portfolio. He previously served as Vice President of Healthcare at Amazon and Chief Digital Officer at Providence St. Joseph Health. CEO Dave Rosa said Martin’s healthcare technology and insurance experience would support Intuitive’s efforts to expand access to minimally invasive care.
Intuitive (Nasdaq: ISRG) reported third-quarter 2026 revenue of $3.05 billion, with procedure growth supporting higher sales across its business. Revenue rose 22% from a year earlier. Worldwide procedures increased approximately 15%, including approximately 14% growth for da Vinci and 31% for Ion. Da Vinci system placements rose to 546 from 427.
GAAP net income attributable to Intuitive fell to $522.8 million, or $1.49 per diluted share, from $704.4 million, or $1.95. Non-GAAP net income, which excludes certain items, rose to $1.05 billion from $867 million. The company repurchased 7.8 million shares for $2.94 billion; cash, cash equivalents and investments declined $1.83 billion during the quarter to $6.80 billion. For 2026, Intuitive expects da Vinci procedure growth of approximately 14%–15%, closer to the midpoint, and a non-GAAP gross margin of 68.7%–69.3%.
Intuitive (ISRG) reported publication of a large systematic review and meta-analysis in Annals of Surgery Open comparing da Vinci robotic-assisted surgery with laparoscopic and open surgery across 13 common benign conditions, using data from more than 14 million procedures over 14 years in 32 countries.
The authors found da Vinci surgery was associated with shorter hospital stays, faster return to work, lower odds of blood transfusion, and reduced pain medication use versus laparoscopic and open approaches, while showing no statistically significant differences in overall complications, infections, readmissions, or 30‑day mortality compared with laparoscopy. Average operative times were longer for da Vinci procedures. The analysis synthesized randomized trials, prospective and retrospective cohort studies, and database studies across gynecology, general, bariatric, urologic, and hernia surgeries.
Intuitive (NASDAQ: ISRG) announced a collaboration with Deion “Coach Prime” Sanders to raise patient and caregiver awareness of surgical options, including robotic-assisted surgery with da Vinci systems. Sanders, who underwent da Vinci robotic surgery for bladder cancer in 2025 after consulting his physician, will share his personal decision-making experience to encourage patients to ask questions and engage in informed discussions with doctors.
According to Intuitive, more than 20 million patients have had surgery using da Vinci systems, which, when performed by trained surgeons, may enable more precise, less invasive procedures than open surgery and, depending on the procedure, may offer fewer complications, shorter recovery and less pain. The company highlights that da Vinci is a surgical tool, not a cancer treatment, outlines key surgical risks, and discloses that Sanders is compensated for his testimonial.
Intuitive (NASDAQ: ISRG) presented its vision for an AI-enabled future of surgical care at the Society of Robotic Surgery conference, describing a five-layer framework that builds from data capture and insights to intraoperative guidance, augmented dexterity, and longer-term supervised autonomy while preserving surgeon control and accountability.
According to Intuitive, the framework leverages real-world data from more than 20 million da Vinci procedures and new vision-language reasoning models that answered complex surgical questions better than general-purpose AI in early testing. Intuitive also hosted a live telesurgery demonstration between Sunnyvale, CA and Atlanta, GA using a da Vinci 5 system on an advanced tissue model with shared control and Force Feedback. The telesurgery software shown is under development, not cleared for clinical use or sale, and its safety and effectiveness have not been established. Intuitive additionally highlighted important safety information and contraindications, including that force feedback needle drivers are contraindicated in hysterectomy and myomectomy.
Intuitive (Nasdaq: ISRG) reported second quarter 2026 revenue of $2.89 billion, up 19% from $2.44 billion a year earlier, driven by approximately 16% growth in combined da Vinci and Ion procedures and higher system leasing revenue.
GAAP net income attributable to Intuitive was $818 million or $2.29 per diluted share, while non-GAAP net income was $1.00 billion or $2.80 per diluted share, both including a $28 million net tariff refund benefit. Intuitive placed 468 da Vinci systems and 55 Ion systems, expanding the da Vinci installed base to 11,710 and Ion to 1,096. Cash, cash equivalents, and investments rose to $8.63 billion. For full-year 2026, the company projects worldwide da Vinci procedure growth of 13.5%–15.5%, non-GAAP gross margin of 68%–69% of revenue, and non-GAAP operating expense growth of 11%–13%.
Intuitive (NASDAQ: ISRG) appointed Taylor Patton as Chief Commercial and Marketing Officer, effective July 1, succeeding Henry Charlton, who becomes Senior Vice President of Global Business Operations.
Patton joins the Executive Leadership team, bringing nearly two decades of experience across Intuitive’s da Vinci, Ion and Digital platforms and leading the global launch and growth of the Ion endoluminal platform.
Intuitive (Nasdaq: ISRG) announced multiple innovations for its da Vinci 5 ecosystem, Force Feedback instruments, and product reliability and security. Enhancements include upgraded telepresence with full-OR camera, live cursor, better audio, mobile console login, new SimNow 2 training modules, and future digital ruler, surgeon-initiated tool eject, and multi-arm targeting features.
According to Intuitive, uses for five Force Feedback instruments rise from six to 15, a dV5 Complete Care plan guarantees 98% uptime while exceeding 99% actual uptime, and more than 1,400 systems have enabled over 380,000 procedures by 12,800 surgeons in 10 countries.
Intuitive (Nasdaq: ISRG) reported Q1 2026 results with revenue of $2.77B, up 23% year-over-year, and GAAP net income of $822M ($2.28 diluted). Worldwide procedures grew ~17%; da Vinci placements were 431 systems. Cash and investments totaled $7.98B at quarter-end.
The company repurchased 2.3 million shares for $1.1B, acquired a business, and issued 2026 guidance including ~13.5%–15.5% da Vinci procedure growth and non-GAAP gross margin of 67.5%–68.5%.
Intuitive (NASDAQ:ISRG) completed its acquisition of the da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica and affiliates, expanding direct operations into Italy, Spain, Portugal, Malta, San Marino and associated territories on March 2, 2026.
The business is integrated into Intuitive’s European commercial organization under Senior VP and GM Dirk Barten, adds ~250 employees, and serves a combined installed base of more than 470 da Vinci systems in Italy, Spain and Portugal; Ion launched recently in Italy and Spain.